Switzerland· 63285001

Entyvio

A vedolizumab product containing vedolizumabum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L04AG05

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedEntyvioATCL04AG05REGISTER NO.63285001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Vedolizumab is registered in 12 of 19 countries.

Countries holding a registration under ATC L04AG05 (vedolizumab), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Vedolizumab · ATC L04AG05

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of vedolizumab costs, country by country.

Normalised to the WHO defined daily dose (5.4 mg), so markets compare like for like.

  • Switzerland: $36.68 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Vedolizumab · price per daily dose (5.4 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$36.68
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
vedolizumabum
Manufacturer
—
Country
Switzerland (CH)
ATC code
L04AG05
ATC class
Vedolizumab
Defined daily dose
5.4 mg, P
Swissmedic category
A
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680632850018
    Durchstf 1 Stk
    CHF 2384.05

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

60 interactions on record for vedolizumab.

Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Vedolizumab · interactions on record

60 records

  • 27 severe
  • 26 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Vedolizumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All vedolizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Entyvio
  • Liechtenstein · Entyvio
  • Norway · Entyvio

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/aa04c764-dc6e-41c9-a1b9-f328d1c11a85
GET /v1/drugs/aa04c764-dc6e-41c9-a1b9-f328d1c11a85?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "vedolizumabum 300 mg",
  "valid_from": "2019-04-01",
  "limitations": "[{\"description\":\"Zur Behandlung von Erwachsenen von mittel- bis hochgradig aktiver Colitis ulcerosa und mittel- bis hochgradig aktivem Morbus Crohn, die auf die Standardtherapie oder einen Antagonisten von Tumornekrosefaktor alpha (TNFα) nicht ausreichend oder nicht mehr ansprachen oder Unverträglichkeit zeigten.<br>\\nBei einem Nicht-Ansprechen bis 14 Wochen soll Entyvio abgesetzt werden.<br>\\nEine Verkürzung des Dosierungsintervalls auf vier Wochen bei Patienten, die eine Verminderung des Therapieansprechens zeigen, sowie eine Weiterbehandlung nach einer Therapie mit Entyvio von einem Jahr bedürfen der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.\\n\",\"costApproval\":null,\"indication\":null,\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2019-04-01\",\"validTo\":null}]",
  "galenic_form": "Trockensub 300 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2015-03-01",
  "self_retention_pct": 10
}

See everything about vedolizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.